Loading...

Esperion Therapeutics

DB:0ET
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0ET
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). The last earnings update was 109 days ago. More info.


Add to Portfolio Compare Print
0ET Share Price and Events
7 Day Returns
1.6%
DB:0ET
3.2%
DE Biotechs
2.9%
DE Market
1 Year Returns
-33.2%
DB:0ET
-3.7%
DE Biotechs
-12.1%
DE Market
0ET Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Esperion Therapeutics (0ET) 1.6% 2.6% 4.6% -33.2% 170.9% -
DE Biotechs 3.2% -3.2% -0.5% -3.7% 88.2% 10.3%
DE Market 2.9% 0.8% 0.2% -12.1% 11.8% 4.9%
1 Year Return vs Industry and Market
  • 0ET underperformed the Biotechs industry which returned -3.7% over the past year.
  • 0ET underperformed the Market in Germany which returned -12.1% over the past year.
Price Volatility
0ET
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Esperion Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Esperion Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Esperion Therapeutics.

DB:0ET Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 11.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:0ET
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 9.8%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.13
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.127 (1 + (1- 21%) (0%))
1.127
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.127 * 9.77%)
11.24%

Discounted Cash Flow Calculation for DB:0ET using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Esperion Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:0ET DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (USD, Millions) -103.00 -193.00 -162.50 13.50 205.00
Source Analyst x4 Analyst x2 Analyst x2 Analyst x2 Analyst x2
Present Value
Discounted (@ 11.24%)
-92.59 -155.95 -118.04 8.81 120.32
Present value of next 5 years cash flows $-237.44
DB:0ET DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= $205.00 × (1 + 0.23%) ÷ (11.24% – 0.23%)
$1,865.03
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= $1,865.03 ÷ (1 + 11.24%)5
$1,094.68
DB:0ET Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= $-237.44 + $1,094.68
$857.24
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $857.24 / 26.81
$28.14
DB:0ET Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:0ET represents 0.8801x of NasdaqGM:ESPR
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8801x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 31.97 x 0.8801
€28.14
Value per share (EUR) From above. €28.14
Current discount Discount to share price of €40.08
= -1 x (€40.08 - €28.14) / €28.14
-42.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Esperion Therapeutics is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Esperion Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Esperion Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0ET PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-6.75
NasdaqGM:ESPR Share Price ** NasdaqGM (2019-02-18) in USD $45.54
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 24.27x
Germany Market PE Ratio Median Figure of 420 Publicly-Listed Companies 18.16x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Esperion Therapeutics.

DB:0ET PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ESPR Share Price ÷ EPS (both in USD)

= 45.54 ÷ -6.75

-6.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Esperion Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Esperion Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Esperion Therapeutics's expected growth come at a high price?
Raw Data
DB:0ET PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
40.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 21 Publicly-Listed Biotechs Companies 1.45x
Germany Market PEG Ratio Median Figure of 277 Publicly-Listed Companies 1.39x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Esperion Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Esperion Therapeutics's assets?
Raw Data
DB:0ET PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $4.92
NasdaqGM:ESPR Share Price * NasdaqGM (2019-02-18) in USD $45.54
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 2.39x
Germany Market PB Ratio Median Figure of 566 Publicly-Listed Companies 1.79x
DB:0ET PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ESPR Share Price ÷ Book Value per Share (both in USD)

= 45.54 ÷ 4.92

9.27x

* Primary Listing of Esperion Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Esperion Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Esperion Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Esperion Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Esperion Therapeutics expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Esperion Therapeutics expected to grow at an attractive rate?
  • Esperion Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Esperion Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Esperion Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:0ET Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0ET Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 40.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 29.7%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 25.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0ET Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0ET Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 783 471 407 3
2022-12-31 515 -26 70 4
2021-12-31 142 -88 -167 3
2020-12-31 137 -141 -176 7
2019-12-31 56 -132 -129 12
2018-12-31 0 -155 -180 11
DB:0ET Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 -155 -180
2018-06-30 -153 -175
2018-03-31 -140 -173
2017-12-31 -131 -167
2017-09-30 -113 -158
2017-06-30 -91 -130
2017-03-31 -72 -101
2016-12-31 -48 -75
2016-09-30 -40 -59
2016-06-30 -37 -55
2016-03-31 -39 -53
2015-12-31 -38 -50

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Esperion Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Esperion Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0ET Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from Esperion Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0ET Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 9.95 10.65 9.24 2.00
2022-12-31 1.74 5.34 -2.64 4.00
2021-12-31 -4.58 -3.91 -5.24 2.00
2020-12-31 -5.33 -4.74 -6.14 4.00
2019-12-31 -4.50 -1.29 -6.70 11.00
2018-12-31 -6.65 -6.14 -6.96 11.00
DB:0ET Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -6.75
2018-06-30 -6.73
2018-03-31 -6.92
2017-12-31 -6.98
2017-09-30 -6.87
2017-06-30 -5.77
2017-03-31 -4.48
2016-12-31 -3.33
2016-09-30 -2.62
2016-06-30 -2.42
2016-03-31 -2.35
2015-12-31 -2.26

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Esperion Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Esperion Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Esperion Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Esperion Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Esperion Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Esperion Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Esperion Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Esperion Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Esperion Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Esperion Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0ET Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 -179.66 27.18 155.45
2018-06-30 -174.97 23.85 153.96
2018-03-31 -172.58 22.30 152.68
2017-12-31 -166.99 21.38 147.60
2017-09-30 -158.05 20.53 139.05
2017-06-30 -130.24 19.06 112.49
2017-03-31 -100.93 18.28 83.94
2016-12-31 -74.98 18.28 57.87
2016-09-30 -59.14 19.16 40.94
2016-06-30 -54.54 20.61 34.69
2016-03-31 -52.90 21.23 32.20
2015-12-31 -49.78 20.24 29.80
2015-09-30 -46.12 18.14 28.05
2015-06-30 -43.12 14.99 27.97
2015-03-31 -39.97 12.47 27.29
2014-12-31 -36.38 10.92 25.30
2014-09-30 -36.61 10.14 26.44
2014-06-30 -32.04 9.54 22.75
2014-03-31 -29.72 7.98 19.32
2013-12-31 -26.09 6.75 16.01
2013-09-30 -19.17 4.85 10.33
2013-06-30 -17.29 3.46 9.30
2013-03-31 -13.53 2.82 8.53
2012-12-31 -11.74 2.21 8.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Esperion Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Esperion Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Esperion Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Esperion Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Esperion Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Esperion Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Esperion Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Esperion Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Esperion Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Esperion Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Esperion Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Esperion Therapeutics Company Filings, last reported 4 months ago.

DB:0ET Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 131.75 0.00 159.22
2018-06-30 175.92 0.15 180.17
2018-03-31 214.14 0.60 197.22
2017-12-31 244.69 1.05 200.20
2017-09-30 278.10 1.48 203.37
2017-06-30 154.11 1.90 167.41
2017-03-31 192.42 2.32 181.88
2016-12-31 228.60 2.73 211.58
2016-09-30 254.18 3.13 210.10
2016-06-30 267.96 3.53 207.18
2016-03-31 277.76 3.91 194.47
2015-12-31 287.26 4.29 212.26
2015-09-30 296.48 4.66 215.60
2015-06-30 305.46 4.90 224.78
2015-03-31 314.43 4.89 278.11
2014-12-31 133.55 4.87 105.84
2014-09-30 50.22 4.93 52.96
2014-06-30 58.91 4.92 59.72
2014-03-31 67.04 0.00 56.70
2013-12-31 74.09 0.00 60.06
2013-09-30 83.23 0.00 71.90
2013-06-30 12.89 0.00 16.63
2013-03-31 19.74 0.00 20.89
2012-12-31 -17.39 22.77 6.51
  • Esperion Therapeutics has no debt.
  • Esperion Therapeutics had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Esperion Therapeutics has less than a year of cash runway based on current free cash flow.
  • Esperion Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 56% each year.
X
Financial health checks
We assess Esperion Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Esperion Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Esperion Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Esperion Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Esperion Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Esperion Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0ET Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 332 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0ET Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 3.00
2019-12-31 0.00 4.00
2018-12-31 0.00 5.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Esperion Therapeutics has not reported any payouts.
  • Unable to verify if Esperion Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Esperion Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Esperion Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Esperion Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Esperion Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Esperion Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Esperion Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Esperion Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tim Mayleben
COMPENSATION $5,013,460
AGE 57
TENURE AS CEO 6.2 years
CEO Bio

Mr. Timothy M. Mayleben, also known as Tim, M.B.A., has been the Chief Executive Officer and President of Esperion Therapeutics, Inc. since December 2012. Mr. Mayleben serves as an Advisor to several biotechnology companies in the Ann Arbor area. Mr. Mayleben serves as the President of ElMa Advisors, LLC. He served as the Chief Operating Officer and Executive Vice President of Nighthawk Radiology Services, LLC since January 2007. Mr. Mayleben served as the Chief Operating Officer of original Esperion, Inc., from April 2002 to 2004 and served as its Chief Financial Officer since January 1999. He joined Esperion in 1998 and was responsible for raising more than $200 million in venture capital and institutional equity funding and negotiated the acquisition of Esperion by Pfizer in 2004. He also served as Senior Vice President of Operations and Finance at Esperion from January 2002 to April 2002 and served as its Vice President of Finance from January 1999 to January 2002. He served as the Chief Executive Officer and President of Aastrom Biosciences Inc. (alternate name Vericel Corporation) since December 14, 2009 until December 14, 2012. He served as the President of NightHawk Radiology Holdings, Inc. since July 25, 2007 and served as its Chief Operating Officer and Executive Vice President from January 8, 2007 to July 25, 2007. Mr. Mayleben served as the Chief Executive Officer and President of Alba Therapeutics Corporation and served as its Chief Financial Officer and Chief Operating Officer. He served as the Chief Financial Officer of Aastrom Biosciences Inc. from December 14, 2009 to June 7, 2010. Mr. Mayleben served as a Consultant with ElMa and has been in advising life science and health care companies since 2004. Mr. Mayleben served as the Director of Business Development for Engineering Animation Inc. from September 1998 to December 1998. From July 1997 to September 1998, he served as the Chief Operating Officer and Chief Financial Officer of Transom Technologies Inc. He raised capital and co-led the negotiations for the sale of Transom to EDS. From September 1990 to July 1997, he served in various managerial positions including as the Director of Operations of Applied Intelligent Systems Inc. Mr. Mayleben served as a Manager with the Enterprise Group of Arthur Andersen & Co. He started his professional career with an international public accounting firm in 1984. Mr. Mayleben serves as a Director for several private life science companies. He has been a Director of Esperion Therapeutics, Inc. since February 2010. He serves as a Member of the Advisory Board at The Wolverine Venture Fund, L.P. He was a Director of Loxo Oncology, Inc. since July 30, 2015 until February 15, 2019. He serves as a Director of kaleo, Inc., and DeNovo Sciences. He has been an Independent Director of Marinus Pharmaceuticals, Inc. since December 2008. Mr. Mayleben served as a Director of Nighthawk Radiology Services, LLC since 2005. Mr. Mayleben served as a Director of Lycera Corp. until March 13, 2017. Mr. Mayleben served as a Director of Aastrom Biosciences, Inc. since June 20, 2005. He served as a Director of Rubicon Genomics, Inc. He served as a Director of Nighthawk Radiology Holdings Inc. since March 2005 and Advanced ICU Care, Inc. since November 2006. Mr. Mayleben also served as a Member of the Board of Directors at Coputer Challenge Inc. He served as a Director of Aksys Ltd. since June 23, 2006. He served as a Member of Advisory Board at Alba Therapeutics Corporation. Mr. Mayleben has more than a decade of executive leadership roles in the life sciences industry. He is also an advisor to, investor in, and member of the board of directors of several life science companies. He is also an active angel investor in Michigan life sciences companies. Mr. Mayleben has an M.B.A. with distinction from the J.L. Kellogg Graduate School of Management at Northwestern University and a B.B.A. from the University Of Michigan, Ross School Of Business.

CEO Compensation
  • Tim's compensation has increased whilst company is loss making.
  • Tim's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Esperion Therapeutics management team in years:

1
Average Tenure
52
Average Age
  • The average tenure for the Esperion Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Tim Mayleben

TITLE
President
COMPENSATION
$5M
AGE
57
TENURE
6.2 yrs

Narendra Lalwani

TITLE
Executive VP of Research & Development
COMPENSATION
$1M
AGE
65

Rick Bartram

TITLE
CFO & Corporate Secretary
AGE
36
TENURE
1.1 yrs

Alex Schwartz

TITLE
Senior Director of Investor Relations
TENURE
0.8 yrs

Marianne Andreach

TITLE
Senior Vice President
TENURE
1.6 yrs

Ashley Hall

TITLE
Senior Vice President of Global Regulatory Affairs & Policy
TENURE
0.8 yrs

Bill Sasiela

TITLE
Senior Vice President of Clinical Development
AGE
52
TENURE
0.8 yrs

Mark Glickman

TITLE
Chief Commercial Officer
AGE
52
TENURE
0.8 yrs

April Seiler

TITLE
Senior Director of Project Management
TENURE
10.8 yrs
Board of Directors Tenure

Average tenure and age of the Esperion Therapeutics board of directors in years:

5
Average Tenure
58.5
Average Age
  • The tenure for the Esperion Therapeutics board of directors is about average.
Board of Directors

Tim Mayleben

TITLE
President
COMPENSATION
$5M
AGE
57
TENURE
9 yrs

Nicole Vitullo

TITLE
Lead Independent Director
COMPENSATION
$403K
AGE
61
TENURE
3.2 yrs

Scott Braunstein

TITLE
Director
COMPENSATION
$396K
AGE
55
TENURE
3.7 yrs

Jay Shepard

TITLE
Director
AGE
60
TENURE
0.8 yrs

Roger Newton

TITLE
Director
COMPENSATION
$464K
AGE
67
TENURE
10.8 yrs

Antonio Gotto

TITLE
Director
COMPENSATION
$387K
AGE
83
TENURE
5.1 yrs

Dov Goldstein

TITLE
Director
COMPENSATION
$344K
AGE
51
TENURE
10.8 yrs

Dan Janney

TITLE
Director
COMPENSATION
$389K
AGE
53
TENURE
6.3 yrs

Mark McGovern

TITLE
Director
COMPENSATION
$382K
AGE
65
TENURE
5 yrs

Jeff Berkowitz

TITLE
Director
AGE
52
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
07. Jan 19 Buy Bellevue Asset Management AG Company 04. Jan 19 04. Jan 19 80,000 €36.22 €2,897,286
26. Dec 18 Buy Bellevue Asset Management AG Company 24. Dec 18 24. Dec 18 50,000 €34.99 €1,749,453
19. Dec 18 Buy Bellevue Asset Management AG Company 17. Dec 18 17. Dec 18 60,000 €42.08 €2,524,678
06. Nov 18 Sell Tavistock Life Sciences Company 02. Nov 18 05. Nov 18 -100,000 €52.87 €-4,944,826
06. Aug 18 Buy Bellevue Asset Management AG Company 03. Aug 18 03. Aug 18 50,000 €39.78 €1,988,839
13. Jul 18 Buy Bellevue Asset Management AG Company 12. Jul 18 12. Jul 18 50,000 €35.74 €1,787,167
03. Jul 18 Buy Bellevue Asset Management AG Company 29. Jun 18 29. Jun 18 50,000 €33.83 €1,691,748
25. Jun 18 Buy Bellevue Asset Management AG Company 21. Jun 18 21. Jun 18 60,000 €33.25 €1,994,861
11. Jun 18 Buy Bellevue Asset Management AG Company 07. Jun 18 07. Jun 18 60,000 €31.96 €1,917,449
07. Jun 18 Buy Bellevue Asset Management AG Company 05. Jun 18 05. Jun 18 60,000 €32.95 €1,976,717
22. May 18 Buy Bellevue Asset Management AG Company 18. May 18 21. May 18 130,000 €35.92 €4,433,790
X
Management checks
We assess Esperion Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Esperion Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Map
Description

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Details
Name: Esperion Therapeutics, Inc.
0ET
Exchange: DB
Founded: 2008
$1,079,584,354
26,811,002
Website: http://www.esperion.com
Address: Esperion Therapeutics, Inc.
3891 Ranchero Drive,
Suite 150,
Ann Arbor,
Michigan, 48108,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ESPR Common Stock Nasdaq Global Market US USD 26. Jun 2013
DB 0ET Common Stock Deutsche Boerse AG DE EUR 26. Jun 2013
LSE 0IIM Common Stock London Stock Exchange GB USD 26. Jun 2013
Number of employees
Current staff
Staff numbers
57
Esperion Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/18 23:25
End of day share price update: 2019/02/18 00:00
Last estimates confirmation: 2019/01/18
Last earnings filing: 2018/11/01
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.